Global PCR-based Infectious Diseases Market - Industry Trends and Forecast to 2031

Description

List of Tables

The global PCR-based infectious diseases market is expected to reach USD 7,720,895.13 thousand by 2031 from USD 4,737,570.00 thousand in 2023, growing with a CAGR of 6.6% in the forecast period of 2024 to 2031.

Market Segmentation

Global PCR-based Infectious Diseases Market, By Test Type (Tuberculosis PCR Test, Hepatitis PCR Test, Human Immunodeficiency Virus (HIV) PCR Test, Influenza PCR Test, Human Papillomavirus (HPV) PCR Test, Gonorrhea PCT Test, Salmonellosis PCR Test, Rotavirus PCR Test, Bordetella PCR Test, H. Pylori PCR Test, Norovirus PCR Test, SARS (COVID-19) PCR Test, Enterococcus PCR Test, Chlamydia Trachomatis Genital PCR Test, C. Difficile (Clostridium Difficile) PCR Test, Carbapenem-Resistant Enterobacteriaceae (CRE) PCR Test, Mycoplasma Genitalium (MG) PCR Test, Methicillin-Resistant Staphylococcus Aureus (MRSA) PCR Test, and Other PCR Test), Infection (Viral Infection, Respiratory Tract Infection, Sexually Transmitted Infection, Hospital Acquired Infections, and Other Infections), Pathogen (Viral, Bacterial, Fungal, Protozoa, and Others), PCR Technology (RT PCR, Multiplex PCR, and Others), Patient Type (Geriatric, Pediatric, and Adults), Testing (Laboratory Based Testing and Point of Care Testing), End User (Diagnostic Centers, Hospital, Academic and Research Institutes, Community Health Centers, Clinics, Home Healthcare, and Others), Country (U.S., Canada, Mexico, Germany, U.K., Italy, France, Spain, Russia, Switzerland, Turkey, Belgium, Netherlands, Hungary, Rest of Europe, Japan, China, South Korea, India, Singapore, Thailand, Indonesia, Malaysia, Philippines, Australia, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Egypt, Saudi Arabia, U.A.E., Israel, and Rest of Middle East and Africa) - Industry Trends and Forecast to 2031

Overview of Global PCR-based Infectious Diseases Market Dynamics

Driver
Increasing PCR-based research activities
Restraint
High cost of PCR test services
Opportunity
Disease surveillance for early detection and monitoring of infectious diseases

Market Players

Some of the major market players operating in the global PCR-based infectious diseases market are:

DNA Labs India
DrSafeHands
Ganesh Diagnostic & Imaging Centre Pvt. Ltd.
Max Lab
MicroGen Diagnostics
pathlab
The Washington Travel Clinic
Clarewell Clinics
AZOVA
One Life Home Health Care Center
LalpathLabs

1 INTRODUCTION 45

1.1 OBJECTIVES OF THE STUDY 45
1.2 MARKET DEFINITION 45
1.3 OVERVIEW OF GLOBAL PCR-BASED INFECTIOUS DISEASES MARKET 45
1.4 CURRENCY AND PRICING 46
1.5 LIMITATIONS 47
1.6 MARKETS COVERED 47

2 MARKET SEGMENTATION 50

2.1 MARKETS COVERED 50
2.2 GEOGRAPHICAL SCOPE 51
2.3 YEARS CONSIDERED FOR THE STUDY 52
2.4 DBMR TRIPOD DATA VALIDATION MODEL 53
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 56
2.6 MULTIVARIATE MODELLING 57
2.7 MARKET APPLICATION COVERAGE GRID 58
2.8 TEST TYPE LIFELINE CURVE 59
2.9 DBMR MARKET POSITION GRID 60
2.10 VENDOR SHARE ANALYSIS 61
2.11 SECONDARY SOURCES 62
2.12 ASSUMPTIONS 62

3 EXECUTIVE SUMMARY 63

4 PREMIUM INSIGHTS 66

4.1 PESTEL ANALYSIS 69
4.2 PORTER'S FIVE FORCES 70

5 MARKET OVERVIEW 71

5.1 DRIVERS 73
- 5.1.1 INCREASING PCR-BASED RESEARCH ACTIVITIES 73
- 5.1.2 RISING CASES OF INFECTIOUS DISEASES 73
- 5.1.3 GOVERNMENT INITIATIVES AND CAMPAIGNS TO PROMOTE DISEASE DIAGNOSIS 74
5.2 RESTRAINTS 75
- 5.2.1 HIGH COST OF PCR TEST SERVICES 75
- 5.2.2 SHORTAGE OF SKILLED LABORATORY TECHNICIANS 76
5.3 OPPORTUNITIES 77
- 5.3.1 DISEASE SURVEILLANCE FOR EARLY DETECTION AND MONITORING OF INFECTIOUS DISEASES 77
- 5.3.2 RISING INNOVATIONS IN PCR TECHNOLOGY 77
- 5.3.3 PERSONALIZED PCR-BASED STRATEGIES FOR TARGETED AND EFFECTIVE INTERVENTIONS 78
5.4 CHALLENGES 79
- 5.4.1 DATA SECURITY AND PRIVACY CONCERNS 79
- 5.4.2 COMPLEXITY AND TECHNICAL EXPERTISE 79

6 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE 81

6.1 OVERVIEW 82
6.2 TUBERCULOSIS PCR TEST 88
6.3 HEPATITIS PCR TEST 88
- 6.3.1 HEPATITIS C PCR TEST 89
- 6.3.2 HEPATITIS B PCR TEST 89
6.4 HUMAN IMMUNODEFICIENCY VIRUS (HIV) PCR TEST 90
6.5 INFLUENZA PCR TEST 90
6.6 HUMAN PAPILLOMAVIRUS (HPV) PCR TEST 91
6.7 CHLAMYDIA TRACHOMATIS GENITAL PCR TEST 91
6.8 GONORRHEA PCR TEST 92
6.9 SALMONELLOSIS PCR TEST 92
6.10 ROTAVIRUS PCR TEST 93
6.11 BORDETELLA PCR TEST 93
6.12 H. PYLORI PCR TEST 94
6.13 SARS (COVID-19) PCR TEST 94
6.14 NOROVIRUS PCR TEST 95
6.15 C.DIFFICILE (CLOSTRIDIUM DIFFICILE) PCR TEST 95
6.16 CARBAPENEM-RESISTANT ENTEROBACTERIACEAE (CRE) PCR TEST 96
6.17 ENTEROCOCCUS PCR TEST 96
6.18 MYCOPLASMA GENITALIUM (MG) PCR TEST 97
6.19 METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) PCR TEST 97
6.20 OTHERS PCR TEST 98

7 GLOBAL PCR-BASED INFECTIOUS DIISEASES MARKET, BY INFECTION 99

7.1 OVERVIEW 100
7.2 VIRAL INFECTION 103
- 7.2.1 SARS (COVID-19) INFECTION 103
- 7.2.2 ROTAVIRUS INFECTION 103
- 7.2.3 NOROVIRUS INFECTION 103
- 7.2.4 OTHERS 104
7.3 RESPIRATORY TRACT INFECTION 104
- 7.3.1 INFLUENZA 104
- 7.3.2 TUBERCULOSIS 104
- 7.3.3 BORDETELLA 105
7.4 SEXUALLY TRANSMITTED INFECTION 105
- 7.4.1 CHLAMYDIA TRACHOMATIS GENITAL INFECTION 106
- 7.4.2 GONORRHEA 106
- 7.4.3 HEAPTITIS 106
- 7.4.4 HUMAN IMMUNODEFICIENCY VIRUS (HIV) 106
- 7.4.5 HUMAN PAPILLOMAVIRUS (HPV) 106
- 7.4.6 MYCOPLASMA GENITALIUM (MG) 106
- 7.4.7 OTHERS 106
7.5 HOSPITAL ACQUIRED INFECTIONS 107
- 7.5.1 C.DIFFICILE (CLOSTRIDIUM DIFFICILE) 107
- 7.5.2 CARBAPENEM- RESISTANT ENTEROBACTERIACEAE (CRE) 107
- 7.5.3 METHICILIN- RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) 108
- 7.5.4 OTHERS 108
7.6 OTHER INFECTIONS 108
- 7.6.1 SALMONELLOSIS 108
- 7.6.2 H. PYLORI 109
- 7.6.3 ENTEROCOCCUS INFECTIONS 109
- 7.6.4 OTHERS 109

8 GLOBAL PCR-BASED INFECTIOUS DIISEASES MARKET, BY PATHOGEN 110

8.1 OVERVIEW 111
8.2 VIRAL 114
8.3 BACTERIAL 114
8.4 FUNGAL 115
8.5 PROTOZOA 115
8.6 OTHERS 116

9 GLOBAL PCR-BASED INFECTIOUS DIISEASES MARKET, BY PCR TECHNOLOGY 117

9.1 OVERVIEW 118
9.2 RT PCR 121
9.3 MULTIPLEX PCR 121
9.4 OTHERS 122

10 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE 123

10.1 OVERVIEW 124
10.2 GERIATRIC 127
10.3 PEDIATRIC 127
10.4 ADULTS 128

11 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING 129

11.1 OVERVIEW 130
11.2 LABORATORY BASED TESTING 133
11.3 POINT OF CARE TESTING 133

12 GLOBAL PCR-BASED INFECTIOUS DISEASES MARKET, BY END USER 134

12.1 OVERVIEW 135
12.2 DIAGNOSTIC CENTERS 138
12.3 HOSPITAL 138
12.4 CLINICS 139
12.5 COMMUNITY HEALTH CENTERS 139
12.6 ACADEMIC AND RESEARCH INSTITUTES 140
12.7 HOME HEALTHCARE 140
12.8 OTHERS 141

13 GLOBAL PCR-BASED INFECTIOUS DISEASES MARKET, BY REGION 142

13.1 OVERVIEW 143
13.2 NORTH AMERICA 147
- 13.2.1 U.S. 156
- 13.2.2 CANADA 164
- 13.2.3 MEXICO 172
13.3 EUROPE 180
- 13.3.1 GERMANY 189
- 13.3.2 FRANCE 197
- 13.3.3 U.K. 205
- 13.3.4 ITALY 213
- 13.3.5 RUSSIA 221
- 13.3.6 SPAIN 229
- 13.3.7 TURKEY 237
- 13.3.8 NETHERLANDS 245
- 13.3.9 SWITZERLAND 253
- 13.3.10 BELGIUM 261
- 13.3.11 HUNGARY 269
- 13.3.12 REST OF EUROPE 277
13.4 ASIA PACIFIC 280
- 13.4.1 CHINA 290
- 13.4.2 AUSTRALIA 298
- 13.4.3 JAPAN 306
- 13.4.4 INDIA 314
- 13.4.5 SOUTH KOREA 322
- 13.4.6 SINGAPORE 330
- 13.4.7 MALAYISA 338
- 13.4.8 THAILAND 346
- 13.4.9 INDONESIA 354
- 13.4.10 PHILIPPINES 362
- 13.4.11 REST OF ASIA-PACIFIC 370
13.5 SOUTH AMERICA 373
- 13.5.1 BRAZIL 382
- 13.5.2 ARGENTINA 390
- 13.5.3 REST OF SOUTH AMERICA 398
13.6 MIDDLE EAST AND AFRICA 401
- 13.6.1 SOUTH AFRICA 410
- 13.6.2 U.A.E. 418
- 13.6.3 SAUDI ARABIA 426
- 13.6.4 EGYPT 434
- 13.6.5 ISRAEL 442
- 13.6.6 REST OF MIDDLE EAST AND AFRICA 450

14 GLOBAL PCR-BASED INFECTIOUS DISEASES MARKET: COMPANY LANDSCAPE 453

14.1 COMPANY SHARE ANALYSIS: GLOBAL 453

15 SWOT ANALYSIS 454

16 COMPANY PROFILE 455

16.1 MICROGEN DIAGNOSTICS 455
- 16.1.1 COMPANY SNAPSHOT 455
- 16.1.2 SERVICE PORTFOLIO 455
- 16.1.3 RECENT DEVELOPMENTS 456
16.2 MAX LAB 457
- 16.2.1 COMPANY SNAPSHOT 457
- 16.2.2 SERVICE PORTFOLIO 457
16.3 DNA LABS INDIA 459
- 16.3.1 COMPANY SNAPSHOT 459
- 16.3.2 SERVICE PORTFOLIO 459
- 16.3.3 RECENT DEVELOPMENT 460
16.4 GANESH DIAGNOSTIC & IMAGING CENTRE PVT. LTD. 461
- 16.4.1 COMPANY SNAPSHOT 461
- 16.4.2 SERVICE PORTFOLIO 461
- 16.4.3 RECENT DEVELOPMENT 462
16.5 LALPATHLABS 463
- 16.5.1 COMPANY SNAPSHOT 463
- 16.5.2 REVENUE ANALYSIS 463
- 16.5.3 PRODUCT PORTFOLIO 464
- 16.5.4 RECENT DEVELOPMENTS 464
16.6 AZOVA 465
- 16.6.1 COMPANY SNAPSHOT 465
- 16.6.2 PRODUCT PORTFOLIO 465
- 16.6.3 RECENT DEVELOPMENTS 465
16.7 CLAREWELL CLINICS 466
- 16.7.1 COMPANY SNAPSHOT 466
- 16.7.2 PRODUCT DESCRIPTION 466
- 16.7.3 RECENT DEVELOPMENTS 466
16.8 DRSAFEHANDS 467
- 16.8.1 COMPANY SNAPSHOT 467
- 16.8.2 SERVICE PORTFOLIO 467
- 16.8.3 RECENT DEVELOPMENT 467
16.9 ONE LIFE HOME HEALTH CARE CENTER 468
- 16.9.1 COMPANY SNAPSHOT 468
- 16.9.2 PRODUCT DESCRIPTION 468
- 16.9.3 RECENT DEVELOPMENTS 468
16.10 PATHLAB 469
- 16.10.1 COMPANY SNAPSHOT 469
- 16.10.2 SERVICE PORTFOLIO 469
- 16.10.3 RECENT DEVELOPMENT 469
16.11 THE WASHINGTON TRAVEL CLINIC 470
- 16.11.1 COMPANY SNAPSHOT 470
- 16.11.2 SERVICE PORTFOLIO 470
- 16.11.3 RECENT DEVELOPMENT 471

17 QUESTIONNAIRE 472

18 RELATED REPORTS 476

LIST OF TABLES

TABLE 1 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 85
TABLE 2 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 86
TABLE 3 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 87
TABLE 4 GLOBAL TUBERCULOSIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 88
TABLE 5 GLOBAL HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 88
TABLE 6 GLOBAL HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 89
TABLE 7 GLOBAL HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 89
TABLE 8 GLOBAL HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 89
TABLE 9 GLOBAL HUMAN IMMUNODEFICIENCY VIRUS (HIV) PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 90
TABLE 10 GLOBAL INFLUENZA PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 90
TABLE 11 GLOBAL HUMAN PAPILLOMAVIRUS (HPV) PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 91
TABLE 12 GLOBAL CHLAMYDIA TRACHOMATIS GENITAL PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 91
TABLE 13 GLOBAL GONORRHEA PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 92
TABLE 14 GLOBAL SALMONELLOSIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 92
TABLE 15 GLOBAL ROTAVIRUS PCR TEST IN PCR BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 93
TABLE 16 GLOBAL BORDETELLA PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 93
TABLE 17 GLOBAL H. PYLORI PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 94
TABLE 18 GLOBAL SARS (COVID-19) PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 94
TABLE 19 GLOBAL NOROVIRUS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 95
TABLE 20 GLOBAL C.DIFFICILE (CLOSTRIDIUM DIFFICILE) PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 95
TABLE 21 GLOBAL CARBAPENEM-RESISTANT ENTEROBACTERIACEAE (CRE) PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 96
TABLE 22 GLOBAL ENTEROCOCCUS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 96
TABLE 23 GLOBAL MYCOPLASMA GENITALIUM (MG) PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 97
TABLE 24 GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 97
TABLE 25 GLOBAL OTHERS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 98
TABLE 26 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 102
TABLE 27 GLOBAL VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 103
TABLE 28 GLOBAL VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 103
TABLE 29 GLOBAL RESPIRATORY TRACT INFECTION IN PCR-BASED INFFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 104
TABLE 30 GLOBAL RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 104
TABLE 31 GLOBAL SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 105
TABLE 32 GLOBAL SEXUALLY TRANSMITTED INFECTION IN VIRAL RESPIRATORY INFECTIONS TREATMENT MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 105
TABLE 33 GLOBAL HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 107
TABLE 34 GLOBAL HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 107
TABLE 35 GLOBAL OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 108
TABLE 36 GLOBAL OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 108
TABLE 37 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND) 113
TABLE 38 GLOBAL VIRAL IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 114
TABLE 39 GLOBAL BACTERIAL IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 114
TABLE 40 GLOBAL FUNGAL IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 115
TABLE 41 GLOBAL PROTOZOA IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 115
TABLE 42 GLOBAL OTHERS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 116
TABLE 43 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND) 120
TABLE 44 GLOBAL RT PCR IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 121
TABLE 45 GLOBAL MULTIPLEX PCR IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 121
TABLE 46 GLOBAL OTHERS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 122
TABLE 47 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 126
TABLE 48 GLOBAL GERIATRIC IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 127
TABLE 49 GLOBAL PEDIATRIC IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 127
TABLE 50 GLOBAL ADULTS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 128
TABLE 51 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND) 132
TABLE 52 GLOBAL LABORATORY BASED TESTING IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 133
TABLE 53 GLOBAL POINT OF CARE TESTING IN PCR-BASED INFECTIOUS DISEASE MARKET, BY REGION, 2022-2031 (USD THOUSAND) 133
TABLE 54 GLOBAL PCR-BASED INFECTIOUS DISEASES MARKET, BY END USER, 2022-2031 (USD THOUSAND) 137
TABLE 55 GLOBAL DIAGNOSTIC CENTERS IN PCR-BASED INFECTIOUS DISEASES MARKET, BY REGION, 2022-2031 (USD THOUSAND) 138
TABLE 56 GLOBAL HOSPITAL IN PCR-BASED INFECTIOUS DISEASES MARKET, BY REGION, 2022-2031 (USD THOUSAND) 138
TABLE 57 GLOBAL CLINICS IN PCR-BASED INFECTIOUS DISEASES MARKET, BY REGION, 2022-2031 (USD THOUSAND) 139
TABLE 58 GLOBAL COMMUNITY HEALTH CENTERS IN PCR-BASED INFECTIOUS DISEASES MARKET, BY REGION, 2022-2031 (USD THOUSAND) 139
TABLE 59 GLOBAL ACADEMIC AND RESEARCH INSTITUTES IN PCR-BASED INFECTIOUS DISEASES MARKET, BY REGION, 2022-2031 (USD THOUSAND) 140
TABLE 60 GLOBAL HOME HEALTHCARE IN PCR-BASED INFECTIOUS DISEASES MARKET, BY REGION, 2022-2031 (USD THOUSAND) 140
TABLE 61 GLOBAL OTHERS IN PCR-BASED INFECTIOUS DISEASES MARKET, BY REGION, 2022-2031 (USD THOUSAND) 141
TABLE 62 GLOBAL PCR-BASED INFECTIOUS DISEASES MARKET, BY REGION, 2022-2031 (USD THOUSAND) 146
TABLE 63 NORTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND) 147
TABLE 64 NORTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 148
TABLE 65 NORTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 149
TABLE 66 NORTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 150
TABLE 67 NORTH AMERICA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 151
TABLE 68 NORTH AMERICA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 151
TABLE 69 NORTH AMERICA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 151
TABLE 70 NORTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 151
TABLE 71 NORTH AMERICA VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 152
TABLE 72 NORTH AMERICA RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 152
TABLE 73 NORTH AMERICA SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 153
TABLE 74 NORTH AMERICA HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 153
TABLE 75 NORTH AMERICA OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 154
TABLE 76 NORTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND) 154
TABLE 77 NORTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND) 154
TABLE 78 NORTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 155
TABLE 79 NORTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND) 155
TABLE 80 NORTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 155
TABLE 81 U.S. PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 156
TABLE 82 U.S. PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 157
TABLE 83 U.S. PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 158
TABLE 84 U.S. HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 159
TABLE 85 U.S. HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 159
TABLE 86 U.S. HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 159
TABLE 87 U.S. PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 159
TABLE 88 U.S. VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 160
TABLE 89 U.S. RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 160
TABLE 90 U.S. SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 161
TABLE 91 U.S. HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 161
TABLE 92 U.S. OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 162
TABLE 93 U.S. PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND) 162
TABLE 94 U.S. PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND) 162
TABLE 95 U.S. PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 163
TABLE 96 U.S. PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND) 163
TABLE 97 U.S. PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 163
TABLE 98 CANADA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 164
TABLE 99 CANADA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 165
TABLE 100 CANADA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 166
TABLE 101 CANADA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 167
TABLE 102 CANADA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 167
TABLE 103 CANADA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 167
TABLE 104 CANADA PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 167
TABLE 105 CANADA VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 168
TABLE 106 CANADA RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 168
TABLE 107 CANADA SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 169
TABLE 108 CANADA HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 169
TABLE 109 CANADA OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 170
TABLE 110 CANADA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND) 170
TABLE 111 CANADA PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND) 170
TABLE 112 CANADA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 171
TABLE 113 CANADA PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND) 171
TABLE 114 CANADA PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 171
TABLE 115 MEXICO PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 172
TABLE 116 MEXICO PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 173
TABLE 117 MEXICO PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 174
TABLE 118 MEXICO HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 175
TABLE 119 MEXICO HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 175
TABLE 120 MEXICO HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 175
TABLE 121 MEXICO PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 175
TABLE 122 MEXICO VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 176
TABLE 123 MEXICO RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 176
TABLE 124 MEXICO SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 177
TABLE 125 MEXICO HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 177
TABLE 126 MEXICO OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 178
TABLE 127 MEXICO PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND) 178
TABLE 128 MEXICO PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND) 178
TABLE 129 MEXICO PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 179
TABLE 130 MEXICO PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND) 179
TABLE 131 MEXICO PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 179
TABLE 132 EUROPE PCR-BASED INFECTIOUS DISEASE MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND) 180
TABLE 133 EUROPE PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 181
TABLE 134 EUROPE PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 182
TABLE 135 EUROPE PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 183
TABLE 136 EUROPE HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 184
TABLE 137 EUROPE HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 184
TABLE 138 EUROPE HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 184
TABLE 139 EUROPE PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 184
TABLE 140 EUROPE VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 185
TABLE 141 EUROPE RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 185
TABLE 142 EUROPE SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 186
TABLE 143 EUROPE HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 186
TABLE 144 EUROPE OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 187
TABLE 145 EUROPE PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND) 187
TABLE 146 EUROPE PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND) 187
TABLE 147 EUROPE PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 188
TABLE 148 EUROPE PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND) 188
TABLE 149 EUROPE PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 188
TABLE 150 GERMANY PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 189
TABLE 151 GERMANY PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 190
TABLE 152 GERMANY PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 191
TABLE 153 GERMANY HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 192
TABLE 154 GERMANY HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 192
TABLE 155 GERMANY HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 192
TABLE 156 GERMANY PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 192
TABLE 157 GERMANY VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 193
TABLE 158 GERMANY RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 193
TABLE 159 GERMANY SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 194
TABLE 160 GERMANY HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 194
TABLE 161 GERMANY OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 195
TABLE 162 GERMANY PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND) 195
TABLE 163 GERMANY PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND) 195
TABLE 164 GERMANY PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 196
TABLE 165 GERMANY PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND) 196
TABLE 166 GERMANY PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 196
TABLE 167 FRANCE PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 197
TABLE 168 FRANCE PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 198
TABLE 169 FRANCE PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 199
TABLE 170 FRANCE HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 200
TABLE 171 FRANCE HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 200
TABLE 172 FRANCE HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 200
TABLE 173 FRANCE PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 200
TABLE 174 FRANCE VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 201
TABLE 175 FRANCE RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 201
TABLE 176 FRANCE SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 202
TABLE 177 FRANCE HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 202
TABLE 178 FRANCE OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 203
TABLE 179 FRANCE PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND) 203
TABLE 180 FRANCE PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND) 203
TABLE 181 FRANCE PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 204
TABLE 182 FRANCE PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND) 204
TABLE 183 FRANCE PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 204
TABLE 184 U.K. PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 205
TABLE 185 U.K. PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 206
TABLE 186 U.K. PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 207
TABLE 187 U.K. HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 208
TABLE 188 U.K. HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 208
TABLE 189 U.K. HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 208
TABLE 190 U.K. PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 208
TABLE 191 U.K. VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 209
TABLE 192 U.K. RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 209
TABLE 193 U.K. SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 210
TABLE 194 U.K. HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 210
TABLE 195 U.K. OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 211
TABLE 196 U.K. PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND) 211
TABLE 197 U.K. PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND) 211
TABLE 198 U.K. PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 212
TABLE 199 U.K. PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND) 212
TABLE 200 U.K. PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 212
TABLE 201 ITALY PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 213
TABLE 202 ITALY PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 214
TABLE 203 ITALY PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 215
TABLE 204 ITALY HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 216
TABLE 205 ITALY HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 216
TABLE 206 ITALY HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 216
TABLE 207 ITALY PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 216
TABLE 208 ITALY VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 217
TABLE 209 ITALY RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 217
TABLE 210 ITALY SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 218
TABLE 211 ITALY HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 218
TABLE 212 ITALY OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 219
TABLE 213 ITALY PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND) 219
TABLE 214 ITALY PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND) 219
TABLE 215 ITALY PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 220
TABLE 216 ITALY PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND) 220
TABLE 217 ITALY PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 220
TABLE 218 RUSSIA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 221
TABLE 219 RUSSIA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 222
TABLE 220 RUSSIA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 223
TABLE 221 RUSSIA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 224
TABLE 222 RUSSIA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 224
TABLE 223 RUSSIA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 224
TABLE 224 RUSSIA PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 224
TABLE 225 RUSSIA VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 225
TABLE 226 RUSSIA RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 225
TABLE 227 RUSSIA SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 226
TABLE 228 RUSSIA HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 226
TABLE 229 RUSSIA OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 227
TABLE 230 RUSSIA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND) 227
TABLE 231 RUSSIA PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND) 227
TABLE 232 RUSSIA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 228
TABLE 233 RUSSIA PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND) 228
TABLE 234 RUSSIA PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 228
TABLE 235 SPAIN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 229
TABLE 236 SPAIN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 230
TABLE 237 SPAIN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 231
TABLE 238 SPAIN HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 232
TABLE 239 SPAIN HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 232
TABLE 240 SPAIN HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 232
TABLE 241 SPAIN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 232
TABLE 242 SPAIN VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 233
TABLE 243 SPAIN RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 233
TABLE 244 SPAIN SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 234
TABLE 245 SPAIN HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 234
TABLE 246 SPAIN OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 235
TABLE 247 SPAIN PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND) 235
TABLE 248 SPAIN PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND) 235
TABLE 249 SPAIN PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 236
TABLE 250 SPAIN PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND) 236
TABLE 251 SPAIN PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 236
TABLE 252 TURKEY PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 237
TABLE 253 TURKEY PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 238
TABLE 254 TURKEY PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 239
TABLE 255 TURKEY HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 240
TABLE 256 TURKEY HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 240
TABLE 257 TURKEY HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 240
TABLE 258 TURKEY PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 240
TABLE 259 TURKEY VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 241
TABLE 260 TURKEY RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 241
TABLE 261 TURKEY SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 242
TABLE 262 TURKEY HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 242
TABLE 263 TURKEY OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 243
TABLE 264 TURKEY PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND) 243
TABLE 265 TURKEY PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND) 243
TABLE 266 TURKEY PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 244
TABLE 267 TURKEY PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND) 244
TABLE 268 TURKEY PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 244
TABLE 269 NETHERLANDS PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 245
TABLE 270 NETHERLANDS PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 246
TABLE 271 NETHERLANDS PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 247
TABLE 272 NETHERLANDS HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 248
TABLE 273 NETHERLANDS HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 248
TABLE 274 NETHERLANDS HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 248
TABLE 275 NETHERLANDS PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 248
TABLE 276 NETHERLANDS VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 249
TABLE 277 NETHERLANDS RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 249
TABLE 278 NETHERLANDS SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 250
TABLE 279 NETHERLANDS HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 250
TABLE 280 NETHERLANDS OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 251
TABLE 281 NETHERLANDS PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND) 251
TABLE 282 NETHERLANDS PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND) 251
TABLE 283 NETHERLANDS PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 252
TABLE 284 NETHERLANDS PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND) 252
TABLE 285 NETHERLANDS PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 252
TABLE 286 SWITZERLAND PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 253
TABLE 287 SWITZERLAND PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 254
TABLE 288 SWITZERLAND PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 255
TABLE 289 SWITZERLAND HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 256
TABLE 290 SWITZERLAND HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 256
TABLE 291 SWITZERLAND HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 256
TABLE 292 SWITZERLAND PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 256
TABLE 293 SWITZERLAND VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 257
TABLE 294 SWITZERLAND RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 257
TABLE 295 SWITZERLAND SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 258
TABLE 296 SWITZERLAND HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 258
TABLE 297 SWITZERLAND OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 259
TABLE 298 SWITZERLAND PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND) 259
TABLE 299 SWITZERLAND PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND) 259
TABLE 300 SWITZERLAND PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 260
TABLE 301 SWITZERLAND PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND) 260
TABLE 302 SWITZERLAND PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 260
TABLE 303 BELGIUM PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 261
TABLE 304 BELGIUM PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 262
TABLE 305 BELGIUM PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 263
TABLE 306 BELGIUM HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 264
TABLE 307 BELGIUM HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 264
TABLE 308 BELGIUM HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 264
TABLE 309 BELGIUM PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 264
TABLE 310 BELGIUM VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 265
TABLE 311 BELGIUM RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 265
TABLE 312 BELGIUM SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 266
TABLE 313 BELGIUM HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 266
TABLE 314 BELGIUM OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 267
TABLE 315 BELGIUM PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND) 267
TABLE 316 BELGIUM PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND) 267
TABLE 317 BELGIUM PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 268
TABLE 318 BELGIUM PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND) 268
TABLE 319 BELGIUM PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 268
TABLE 320 HUNGARY PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 269
TABLE 321 HUNGARY PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 270
TABLE 322 HUNGARY PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 271
TABLE 323 HUNGARY HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 272
TABLE 324 HUNGARY HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 272
TABLE 325 HUNGARY HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 272
TABLE 326 HUNGARY PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 272
TABLE 327 HUNGARY VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 273
TABLE 328 HUNGARY RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 273
TABLE 329 HUNGARY SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 274
TABLE 330 HUNGARY HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 274
TABLE 331 HUNGARY OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 275
TABLE 332 HUNGARY PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND) 275
TABLE 333 HUNGARY PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND) 275
TABLE 334 HUNGARY PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 276
TABLE 335 HUNGARY PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND) 276
TABLE 336 HUNGARY PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 276
TABLE 337 REST OF EUROPE PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 277
TABLE 338 REST OF EUROPE PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 278
TABLE 339 REST OF EUROPE PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 279
TABLE 340 ASIA-PACIFIC PCR-BASED INFECTIOUS DISEASE MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND) 280
TABLE 341 ASIA-PACIFIC PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 281
TABLE 342 ASIA-PACIFIC PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 282
TABLE 343 ASIA-PACIFIC PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 283
TABLE 344 ASIA-PACIFIC HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 284
TABLE 345 ASIA-PACIFIC HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 284
TABLE 346 ASIA-PACIFIC HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 284
TABLE 347 ASIA-PACIFIC PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 284
TABLE 348 ASIA-PACIFIC VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 285
TABLE 349 ASIA-PACIFIC RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 285
TABLE 350 ASIA-PACIFIC SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 286
TABLE 351 ASIA-PACIFIC HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 286
TABLE 352 ASIA-PACIFIC OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 287
TABLE 353 ASIA-PACIFIC PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND) 287
TABLE 354 ASIA-PACIFIC PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND) 288
TABLE 355 ASIA-PACIFIC PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 288
TABLE 356 ASIA-PACIFIC PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND) 288
TABLE 357 ASIA-PACIFIC PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 289
TABLE 358 CHINA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 290
TABLE 359 CHINA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 291
TABLE 360 CHINA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 292
TABLE 361 CHINA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 293
TABLE 362 CHINA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 293
TABLE 363 CHINA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 293
TABLE 364 CHINA PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 293
TABLE 365 CHINA VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 294
TABLE 366 CHINA RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 294
TABLE 367 CHINA SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 295
TABLE 368 CHINA HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 295
TABLE 369 CHINA OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 296
TABLE 370 CHINA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND) 296
TABLE 371 CHINA PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND) 296
TABLE 372 CHINA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 297
TABLE 373 CHINA PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND) 297
TABLE 374 CHINA PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 297
TABLE 375 AUSTRALIA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 298
TABLE 376 AUSTRALIA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 299
TABLE 377 AUSTRALIA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 300
TABLE 378 AUSTRALIA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 301
TABLE 379 AUSTRALIA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 301
TABLE 380 AUSTRALIA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 301
TABLE 381 AUSTRALIA PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 301
TABLE 382 AUSTRALIA VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 302
TABLE 383 AUSTRALIA RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 302
TABLE 384 AUSTRALIA SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 303
TABLE 385 AUSTRALIA HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 303
TABLE 386 AUSTRALIA OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 304
TABLE 387 AUSTRALIA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND) 304
TABLE 388 AUSTRALIA PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND) 304
TABLE 389 AUSTRALIA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 305
TABLE 390 AUSTRALIA PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND) 305
TABLE 391 AUSTRALIA PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 305
TABLE 392 JAPAN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 306
TABLE 393 JAPAN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 307
TABLE 394 JAPAN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 308
TABLE 395 JAPAN HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 309
TABLE 396 JAPAN HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 309
TABLE 397 JAPAN HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 309
TABLE 398 JAPAN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 309
TABLE 399 JAPAN VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 310
TABLE 400 JAPAN RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 310
TABLE 401 JAPAN SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 311
TABLE 402 JAPAN HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 311
TABLE 403 JAPAN OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 312
TABLE 404 JAPAN PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND) 312
TABLE 405 JAPAN PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND) 312
TABLE 406 JAPAN PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 313
TABLE 407 JAPAN PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND) 313
TABLE 408 JAPAN PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 313
TABLE 409 INDIA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 314
TABLE 410 INDIA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 315
TABLE 411 INDIA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 316
TABLE 412 INDIA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 317
TABLE 413 INDIA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 317
TABLE 414 INDIA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 317
TABLE 415 INDIA PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 317
TABLE 416 INDIA VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 318
TABLE 417 INDIA RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 318
TABLE 418 INDIA SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 319
TABLE 419 INDIA HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 319
TABLE 420 INDIA OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 320
TABLE 421 INDIA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND) 320
TABLE 422 INDIA PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND) 320
TABLE 423 INDIA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 321
TABLE 424 INDIA PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND) 321
TABLE 425 INDIA PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 321
TABLE 426 SOUTH KOREA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 322
TABLE 427 SOUTH KOREA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 323
TABLE 428 SOUTH KOREA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 324
TABLE 429 SOUTH KOREA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 325
TABLE 430 SOUTH KOREA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 325
TABLE 431 SOUTH KOREA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 325
TABLE 432 SOUTH KOREA PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 325
TABLE 433 SOUTH KOREA VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 326
TABLE 434 SOUTH KOREA RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 326
TABLE 435 SOUTH KOREA SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 327
TABLE 436 SOUTH KOREA HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 327
TABLE 437 SOUTH KOREA OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 328
TABLE 438 SOUTH KOREA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND) 328
TABLE 439 SOUTH KOREA PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND) 328
TABLE 440 SOUTH KOREA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 329
TABLE 441 SOUTH KOREA PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND) 329
TABLE 442 SOUTH KOREA PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 329
TABLE 443 SINGAPORE PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 330
TABLE 444 SINGAPORE PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 331
TABLE 445 SINGAPORE PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 332
TABLE 446 SINGAPORE HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 333
TABLE 447 SINGAPORE HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 333
TABLE 448 SINGAPORE HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 333
TABLE 449 SINGAPORE PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 333
TABLE 450 SINGAPORE VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 334
TABLE 451 SINGAPORE RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 334
TABLE 452 SINGAPORE SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 335
TABLE 453 SINGAPORE HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 335
TABLE 454 SINGAPORE OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 336
TABLE 455 SINGAPORE PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND) 336
TABLE 456 SINGAPORE PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND) 336
TABLE 457 SINGAPORE PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 337
TABLE 458 SINGAPORE PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND) 337
TABLE 459 SINGAPORE PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 337
TABLE 460 MALAYSIA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 338
TABLE 461 MALAYSIA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 339
TABLE 462 MALAYSIA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 340
TABLE 463 MALAYSIA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 341
TABLE 464 MALAYSIA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 341
TABLE 465 MALAYSIA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 341
TABLE 466 MALAYSIA PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 341
TABLE 467 MALAYSIA VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 342
TABLE 468 MALAYSIA RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 342
TABLE 469 MALAYSIA SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 343
TABLE 470 MALAYSIA HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 343
TABLE 471 MALAYSIA OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 344
TABLE 472 MALAYSIA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND) 344
TABLE 473 MALAYSIA PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND) 344
TABLE 474 MALAYSIA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 345
TABLE 475 MALAYSIA PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND) 345
TABLE 476 MALAYSIA PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 345
TABLE 477 THAILAND PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 346
TABLE 478 THAILAND PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 347
TABLE 479 THAILAND PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 348
TABLE 480 THAILAND HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 349
TABLE 481 THAILAND HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 349
TABLE 482 THAILAND HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 349
TABLE 483 THAILAND PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 349
TABLE 484 THAILAND VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 350
TABLE 485 THAILAND RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 350
TABLE 486 THAILAND SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 351
TABLE 487 THAILAND HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 351
TABLE 488 THAILAND OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 352
TABLE 489 THAILAND PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND) 352
TABLE 490 THAILAND PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND) 352
TABLE 491 THAILAND PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 353
TABLE 492 THAILAND PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND) 353
TABLE 493 THAILAND PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 353
TABLE 494 INDONESIA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 354
TABLE 495 INDONESIA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 355
TABLE 496 INDONESIA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 356
TABLE 497 INDONESIA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 357
TABLE 498 INDONESIA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 357
TABLE 499 INDONESIA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 357
TABLE 500 INDONESIA PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 357
TABLE 501 INDONESIA VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 358
TABLE 502 INDONESIA RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 358
TABLE 503 INDONESIA SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 359
TABLE 504 INDONESIA HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 359
TABLE 505 INDONESIA OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 360
TABLE 506 INDONESIA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND) 360
TABLE 507 INDONESIA PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND) 360
TABLE 508 INDONESIA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 361
TABLE 509 INDONESIA PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND) 361
TABLE 510 INDONESIA PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 361
TABLE 511 PHILIPPINES PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 362
TABLE 512 PHILIPPINES PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 363
TABLE 513 PHILIPPINES PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 364
TABLE 514 PHILIPPINES HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 365
TABLE 515 PHILIPPINES HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 365
TABLE 516 PHILIPPINES HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 365
TABLE 517 PHILIPPINES PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 365
TABLE 518 PHILIPPINES VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 366
TABLE 519 PHILIPPINES RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 366
TABLE 520 PHILIPPINES SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 367
TABLE 521 PHILIPPINES HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 367
TABLE 522 PHILIPPINES OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 368
TABLE 523 PHILIPPINES PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND) 368
TABLE 524 PHILIPPINES PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND) 368
TABLE 525 PHILIPPINES PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 369
TABLE 526 PHILIPPINES PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND) 369
TABLE 527 PHILIPPINES PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 369
TABLE 528 REST OF ASIA-PACIFIC PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 370
TABLE 529 REST OF ASIA-PACIFIC PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 371
TABLE 530 REST OF ASIA-PACIFIC PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 372
TABLE 531 SOUTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND) 373
TABLE 532 SOUTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 374
TABLE 533 SOUTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 375
TABLE 534 SOUTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 376
TABLE 535 SOUTH AMERICA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 377
TABLE 536 SOUTH AMERICA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 377
TABLE 537 SOUTH AMERICA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 377
TABLE 538 SOUTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 377
TABLE 539 SOUTH AMERICA VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 378
TABLE 540 SOUTH AMERICA RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 378
TABLE 541 SOUTH AMERICA SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 379
TABLE 542 SOUTH AMERICA HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 379
TABLE 543 SOUTH AMERICA OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 380
TABLE 544 SOUTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND) 380
TABLE 545 SOUTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND) 380
TABLE 546 SOUTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 381
TABLE 547 SOUTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND) 381
TABLE 548 SOUTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 381
TABLE 549 BRAZIL PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 382
TABLE 550 BRAZIL PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 383
TABLE 551 BRAZIL PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 384
TABLE 552 BRAZIL HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 385
TABLE 553 BRAZIL HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 385
TABLE 554 BRAZIL HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 385
TABLE 555 BRAZIL PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 385
TABLE 556 BRAZIL VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 386
TABLE 557 BRAZIL RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 386
TABLE 558 BRAZIL SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 387
TABLE 559 BRAZIL HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 387
TABLE 560 BRAZIL OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 388
TABLE 561 BRAZIL PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND) 388
TABLE 562 BRAZIL PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND) 388
TABLE 563 BRAZIL PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 389
TABLE 564 BRAZIL PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND) 389
TABLE 565 BRAZIL PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 389
TABLE 566 ARGENTINA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 390
TABLE 567 ARGENTINA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 391
TABLE 568 ARGENTINA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 392
TABLE 569 ARGENTINA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 393
TABLE 570 ARGENTINA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 393
TABLE 571 ARGENTINA HEPATITIS PCR TEST IN PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 393
TABLE 572 ARGENTINA PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 393
TABLE 573 ARGENTINA VIRAL INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 394
TABLE 574 ARGENTINA RESPIRATORY TRACT INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 394
TABLE 575 ARGENTINA SEXUALLY TRANSMITTED INFECTION IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 395
TABLE 576 ARGENTINA HOSPITAL ACQUIRED INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 395
TABLE 577 ARGENTINA OTHER INFECTIONS IN PCR-BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 396
TABLE 578 ARGENTINA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND) 396
TABLE 579 ARGENTINA PCR-BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND) 396
TABLE 580 ARGENTINA PCR-BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 397
TABLE 581 ARGENTINA PCR-BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND) 397
TABLE 582 ARGENTINA PCR-BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 397
TABLE 583 REST OF SOUTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 398
TABLE 584 REST OF SOUTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 399
TABLE 585 REST OF SOUTH AMERICA PCR-BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 400
TABLE 586 MIDDLE EAST AND AFRICA PCR BASED INFECTIOUS DISEASE MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND) 401
TABLE 587 MIDDLE EAST AND AFRICA PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 402
TABLE 588 MIDDLE EAST AND AFRICA PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 403
TABLE 589 MIDDLE EAST AND AFRICA PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 404
TABLE 590 MIDDLE EAST AND AFRICA HEPATITIS PCR TEST IN PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 405
TABLE 591 MIDDLE EAST AND AFRICA HEPATITIS PCR TEST IN PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 405
TABLE 592 MIDDLE EAST AND AFRICA HEPATITIS PCR TEST IN PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 405
TABLE 593 MIDDLE EAST AND AFRICA PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 405
TABLE 594 MIDDLE EAST AND AFRICA VIRAL INFECTION IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 406
TABLE 595 MIDDLE EAST AND AFRICA RESPIRATORY TRACT INFECTION IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 406
TABLE 596 MIDDLE EAST AND AFRICA SEXUALLY TRANSMITTED INFECTION IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 407
TABLE 597 MIDDLE EAST AND AFRICA HOSPITAL ACQUIRED INFECTIONS IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 407
TABLE 598 MIDDLE EAST AND AFRICA OTHER INFECTIONS IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 408
TABLE 599 MIDDLE EAST AND AFRICA PCR BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND) 408
TABLE 600 MIDDLE EAST AND AFRICA PCR BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND) 408
TABLE 601 MIDDLE EAST AND AFRICA PCR BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 409
TABLE 602 MIDDLE EAST AND AFRICA PCR BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND) 409
TABLE 603 MIDDLE EAST AND AFRICA PCR BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 409
TABLE 604 SOUTH AFRICA PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 410
TABLE 605 SOUTH AFRICA PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 411
TABLE 606 SOUTH AFRICA PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 412
TABLE 607 SOUTH AFRICA HEPATITIS PCR TEST IN PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 413
TABLE 608 SOUTH AFRICA HEPATITIS PCR TEST IN PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 413
TABLE 609 SOUTH AFRICA HEPATITIS PCR TEST IN PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 413
TABLE 610 SOUTH AFRICA PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 413
TABLE 611 SOUTH AFRICA VIRAL INFECTION IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 414
TABLE 612 SOUTH AFRICA RESPIRATORY TRACT INFECTION IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 414
TABLE 613 SOUTH AFRICA SEXUALLY TRANSMITTED INFECTION IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 415
TABLE 614 SOUTH AFRICA HOSPITAL ACQUIRED INFECTIONS IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 415
TABLE 615 SOUTH AFRICA OTHER INFECTIONS IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 416
TABLE 616 SOUTH AFRICA PCR BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND) 416
TABLE 617 SOUTH AFRICA PCR BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND) 416
TABLE 618 SOUTH AFRICA PCR BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 417
TABLE 619 SOUTH AFRICA PCR BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND) 417
TABLE 620 SOUTH AFRICA PCR BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 417
TABLE 621 U.A.E. PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 418
TABLE 622 U.A.E. PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 419
TABLE 623 U.A.E. PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 420
TABLE 624 U.A.E. HEPATITIS PCR TEST IN PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 421
TABLE 625 U.A.E. HEPATITIS PCR TEST IN PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 421
TABLE 626 U.A.E. HEPATITIS PCR TEST IN PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 421
TABLE 627 U.A.E. PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 421
TABLE 628 U.A.E. VIRAL INFECTION IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 422
TABLE 629 U.A.E. RESPIRATORY TRACT INFECTION IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 422
TABLE 630 U.A.E. SEXUALLY TRANSMITTED INFECTION IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 423
TABLE 631 U.A.E. HOSPITAL ACQUIRED INFECTIONS IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 423
TABLE 632 U.A.E. OTHER INFECTIONS IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 424
TABLE 633 U.A.E. PCR BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND) 424
TABLE 634 U.A.E. PCR BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND) 424
TABLE 635 U.A.E. PCR BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 425
TABLE 636 U.A.E. PCR BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND) 425
TABLE 637 U.A.E. PCR BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 425
TABLE 638 SAUDI ARABIA PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 426
TABLE 639 SAUDI ARABIA PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 427
TABLE 640 SAUDI ARABIA PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 428
TABLE 641 SAUDI ARABIA HEPATITIS PCR TEST IN PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 429
TABLE 642 SAUDI ARABIA HEPATITIS PCR TEST IN PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 429
TABLE 643 SAUDI ARABIA HEPATITIS PCR TEST IN PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 429
TABLE 644 SAUDI ARABIA PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 429
TABLE 645 SAUDI ARABIA VIRAL INFECTION IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 430
TABLE 646 SAUDI ARABIA RESPIRATORY TRACT INFECTION IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 430
TABLE 647 SAUDI ARABIA SEXUALLY TRANSMITTED INFECTION IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 431
TABLE 648 SAUDI ARABIA HOSPITAL ACQUIRED INFECTIONS IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 431
TABLE 649 SAUDI ARABIA OTHER INFECTIONS IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 432
TABLE 650 SAUDI ARABIA PCR BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND) 432
TABLE 651 SAUDI ARABIA PCR BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND) 432
TABLE 652 SAUDI ARABIA PCR BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 433
TABLE 653 SAUDI ARABIA PCR BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND) 433
TABLE 654 SAUDI ARABIA PCR BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 433
TABLE 655 EGYPT PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 434
TABLE 656 EGYPT PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 435
TABLE 657 EGYPT PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 436
TABLE 658 EGYPT HEPATITIS PCR TEST IN PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 437
TABLE 659 EGYPT HEPATITIS PCR TEST IN PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 437
TABLE 660 EGYPT HEPATITIS PCR TEST IN PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 437
TABLE 661 EGYPT PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 437
TABLE 662 EGYPT VIRAL INFECTION IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 438
TABLE 663 EGYPT RESPIRATORY TRACT INFECTION IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 438
TABLE 664 EGYPT SEXUALLY TRANSMITTED INFECTION IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 439
TABLE 665 EGYPT HOSPITAL ACQUIRED INFECTIONS IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 439
TABLE 666 EGYPT OTHER INFECTIONS IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 440
TABLE 667 EGYPT PCR BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND) 440
TABLE 668 EGYPT PCR BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND) 440
TABLE 669 EGYPT PCR BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 441
TABLE 670 EGYPT PCR BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND) 441
TABLE 671 EGYPT PCR BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 441
TABLE 672 ISRAEL PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 442
TABLE 673 ISRAEL PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 443
TABLE 674 ISRAEL PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 444
TABLE 675 ISRAEL HEPATITIS PCR TEST IN PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 445
TABLE 676 ISRAEL HEPATITIS PCR TEST IN PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 445
TABLE 677 ISRAEL HEPATITIS PCR TEST IN PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 445
TABLE 678 ISRAEL PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 445
TABLE 679 ISRAEL VIRAL INFECTION IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 446
TABLE 680 ISRAEL RESPIRATORY TRACT INFECTION IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 446
TABLE 681 ISRAEL SEXUALLY TRANSMITTED INFECTION IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 447
TABLE 682 ISRAEL HOSPITAL ACQUIRED INFECTIONS IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 447
TABLE 683 ISRAEL OTHER INFECTIONS IN PCR BASED INFECTIOUS DISEASE MARKET, BY INFECTION, 2022-2031 (USD THOUSAND) 448
TABLE 684 ISRAEL PCR BASED INFECTIOUS DISEASE MARKET, BY PATHOGEN, 2022-2031 (USD THOUSAND) 448
TABLE 685 ISRAEL PCR BASED INFECTIOUS DISEASE MARKET, BY PCR TECHNOLOGY, 2022-2031 (USD THOUSAND) 448
TABLE 686 ISRAEL PCR BASED INFECTIOUS DISEASE MARKET, BY PATIENT TYPE, 2022-2031 (USD THOUSAND) 449
TABLE 687 ISRAEL PCR BASED INFECTIOUS DISEASE MARKET, BY TESTING, 2022-2031 (USD THOUSAND) 449
TABLE 688 ISRAEL PCR BASED INFECTIOUS DISEASE MARKET, BY END USER, 2022-2031 (USD THOUSAND) 449
TABLE 689 REST OF MIDDLE EAST AND AFRICA PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (USD THOUSAND) 450
TABLE 690 REST OF MIDDLE EAST AND AFRICA PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (VOLUME) 451
TABLE 691 REST OF MIDDLE EAST AND AFRICA PCR BASED INFECTIOUS DISEASE MARKET, BY TEST TYPE, 2022-2031 (ASP) 452

LIST OF FIGURES

FIGURE 1 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET: SEGMENTATION 50
FIGURE 2 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET: DATA TRIANGULATION 53
FIGURE 3 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET: DROC ANALYSIS 54
FIGURE 4 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS 55
FIGURE 5 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET: COMPANY RESEARCH ANALYSIS 55
FIGURE 6 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET: INTERVIEW DEMOGRAPHICS 56
FIGURE 7 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET: MARKET APPLICATION COVERAGE GRID 58
FIGURE 8 GLOBAL PCR BASED INFECTIOUS DISEASE MARKET: DBMR MARKET POSITION GRID 60
FIGURE 9 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET: VENDOR SHARE ANALYSIS 61
FIGURE 10 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET: SEGMENTATION 65
FIGURE 11 THE GOVERNMENT INITIATIVES AND CAMPAIGNS TO PROMOTE DISEASE DIAGNOSIS IS DRIVING THE GROWTH OF THE GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET FROM 2024 TO 2031 66
FIGURE 12 THE INFECTION TYPE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET IN 2024 AND 2031 66
FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET, AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2024 TO 2031 67
FIGURE 14 ASIA-PACIFIC IS THE FASTEST-GROWING MARKET FOR PCR-BASED INFECTIOUS DISEASE MARKET MANUFACTURERS IN THE FORECAST PERIOD OF 2024 TO 2031 68
FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE GLOBAL PCR-BASED INFECTIOUS DISEASES MARKET 72
FIGURE 16 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET : BY TEST TYPE, 2023 82
FIGURE 17 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET : BY TEST TYPE, 2024-2031 (USD THOUSAND) 83
FIGURE 18 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET : BY TEST TYPE, CAGR (2024-2031) 83
FIGURE 19 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET : BY TEST TYPE, LIFELINE CURVE 84
FIGURE 20 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET: BY INFECTION, 2023 100
FIGURE 21 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET: BY INFECTION, 2024-2031 (USD THOUSAND) 101
FIGURE 22 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET: BY INFECTION, CAGR (2024-2031) 101
FIGURE 23 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET: BY INFECTION, LIFELINE CURVE 102
FIGURE 24 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET: BY PATHOGEN, 2023 111
FIGURE 25 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET: BY PATHOGEN, 2024-2031 (USD THOUSAND) 112
FIGURE 26 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET: BY PATHOGEN, CAGR (2024-2031) 112
FIGURE 27 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET: BY PATHOGEN, LIFELINE CURVE 113
FIGURE 28 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET: BY PCR TECHNOLOGY, 2023 118
FIGURE 29 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET: BY PCR TECHNOLOGY, 2024-2031 (USD THOUSAND) 119
FIGURE 30 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET: BY PCR TECHNOLOGY, CAGR (2024-2031) 119
FIGURE 31 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET: BY PCR TECHNOLOGY, LIFELINE CURVE 120
FIGURE 32 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET : BY PATIENT TYPE, 2023 124
FIGURE 33 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET : BY PATIENT TYPE, 2024-2031 (USD THOUSAND) 125
FIGURE 34 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET : BY PATIENT TYPE, CAGR (2024-2031) 125
FIGURE 35 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET : BY PATIENT TYPE, LIFELINE CURVE 126
FIGURE 36 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET : BY TESTING, 2023 130
FIGURE 37 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET : BY TESTING, 2024-2031 (USD THOUSAND) 131
FIGURE 38 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET : BY TESTING, CAGR (2024-2031) 131
FIGURE 39 GLOBAL PCR-BASED INFECTIOUS DISEASE MARKET : BY TESTING, LIFELINE CURVE 132
FIGURE 40 GLOBAL PCR-BASED INFECTIOUS DISEASES MARKET: BY END USER, 2023 135
FIGURE 41 GLOBAL PCR-BASED INFECTIOUS DISEASES MARKET: BY END USER, 2024-2031 (USD THOUSAND) 136
FIGURE 42 GLOBAL PCR-BASED INFECTIOUS DISEASES MARKET: BY END USER, CAGR (2024-2031) 136
FIGURE 43 GLOBAL PCR-BASED INFECTIOUS DISEASES MARKET: BY END USER, LIFELINE CURVE 137
FIGURE 44 GLOBAL PCR-BASED INFECTIOUS DISEASES MARKET: SNAPSHOT (2023) 144
FIGURE 45 GLOBAL PCR-BASED INFECTIOUS DISEASES MARKET: COMPANY SHARE 2023 (%) 453